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doi:10.1Objective: Ascending aortic aneurysms result from a degenerative process in the aortic wall, characterized by
the loss of smooth muscle cells and elastic fibers.We hypothesized that there would be changes in plasma protein
and aortic tissue messenger RNA levels of osteopontin, matrix metalloproteinase type 2, matrix metalloprotei-
nase type 9, and tissue inhibitor of matrix metalloproteinases type 1 in ascending aortic aneurysm samples.
Methods: Plasma, aortic tissue, and aortic mRNA samples were collected from patients with an ascending aortic
aneurysm or an abdominal aortic aneurysm and from control individuals. Plasma protein levels of osteopontin,
matrix metalloproteinase (MMP) types 2 and 9, and tissue inhibitor of matrix metalloproteinases type 1 were
determined by quantitative sandwich enzyme-linked immunosorbent assay. Aortic mRNA levels of these
same proteins were analyzed with the quantitative real-time polymerase chain reaction (RT-PCR) method
and protein levels from the aortic tissues were assayed by immunostaining. Quantitative RT-PCR results
were estimated by the normalized expression method (DDCt).
Results: Plasma protein levels were significantly elevated for osteopontin, MMP-2, and MMP-9 in the samples
of ascending and abdominal aortic aneurysm group compared with controls. Plasma protein levels of MMP-9
were higher in the nonoperated compared with the operated ascending aortic aneurysm group. Aortic osteopon-
tin, MMP-2, and MMP-9 mRNA levels were increased for ascending aortic aneurysm samples.
Conclusions: This study reveals an important role of osteopontin, MMP-2 and MMP-9 in the development of
ascending and abdominal aortic aneurysm. (J Thorac Cardiovasc Surg 2013;145:1117-23)Aneurysmal disease is characterized by a progressive de-
struction of the connective tissue in arterial wall. This is
due to an imbalance between biomechanical and biological
protecting and predisposing factors.1 Most ascending aortic
aneurysms (AscAA) are due to a degenerative process char-
acterized by the loss of smooth muscle cells and elastin
fibers. Only a minority of AscAAs are caused by known
connective tissue diseases, like Marfan syndrome. On the
other hand, abdominal aortic aneurysms (AAAs) have
a much more atherosclerotic background in comparison
with the AscAAs.2 Previous studies have shown that matrix
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Scardiovascular disorders like aortic dissection, AscAAs,
and AAAs.3-5 MMPs, especially MMP-2 and MMP-9, are
involved in the degradation of extracellular matrix proteins
as well as in tissue remodeling. The proteolytic activity of
MMPs is tightly controlled by plasma proteins and their
endogenous tissue inhibitors, TIMPs (tissue inhibitor of ma-
trix metalloproteinase). The balance between MMP-9 and
TIMP-1 is essential to maintain aortic tissue integrity.6
Osteopontin (OPN) plays a role in the synthesis of collagen
fibers during tissue remodeling and up-regulates the expres-
sion of MMPs. Furthermore, it has been associated with the
development of aortic aneurysms.7 There are also studies
reporting elevated serum levels of OPN in patients with
AAAs.2
MMPs, TIMPs, and OPN play a major role in the process
leading to aneurysm formation inasmuch as the smooth
muscle cells of the aortic wall release these proteins during
matrix degradation. The aim of our study was to evaluate
the plasma levels of OPN, MMP-2, MMP-9, and TIMP-1
and the levels of these proteins in the aortic samples of
the patients with AscAAs, AAAs, as well as in healthy in-
dividuals. Our second aim was to evaluate the levels of
OPN, MMP-2, MMP-9, and TIMP-1 gene expression
from the aortic tissues of AscAA and controls. We hypoth-
esized that levels of these proteins in plasma and in aorticdiovascular Surgery c Volume 145, Number 4 1117
Abbreviations and Acronyms
AAA ¼ abdominal aortic aneurysm
AscAA ¼ ascending aortic aneurysm
CI ¼ confidence interval for OR
CAD ¼ coronary artery disease
MAB ¼ monoclonal antibody
MMP ¼ matrix metalloproteinase
mRNA ¼ messenger RNA
TIMP ¼ tissue inhibitor of matrix
metalloproteinase
OPN ¼ osteopontin
OR ¼ odds ratio
RT-PCR ¼ real-time polymerase chain reaction




Ssamples would be different between aortic aneurysms and
healthy individuals. To study whether the protein levels
and expression are different between nonatherosclerotic
AscAA and atherosclerotic AAA, we also included AAA
patients in the study.
METHODS
Study Subjects
We recruited all the patients who received a diagnosis (either operated
or nonoperated, ie, only diagnosed for follow-up) during the years 1996 to
2007 for AscAA in the Oulu University Hospital in the current study, and
patients who provided informed consent were included in the study. For op-
erated study subjects, the blood samples were taken after the operation, and
a minimum time from the operation to blood sample collection was
4 months. Patients with AscAA related to thoracic trauma or to a previous
aortic operation and patients with Marfan syndrome were excluded. Blood
samples from a total of 97 AscAA patients and 23 AAA patients were col-
lected for the quantitative sandwich enzyme-linked immunosorbent assay
study. A total of 78 subjects without any diagnosis of aneurysmal disease
served as control subjects and were collected from Ophthalmological
Unit of Oulu University Hospital.
Samples of the aortic tissues intended for the quantitative real-time
polymerase chain reaction (RT-PCR) and immunostaining study were col-
lected during the aortic or coronary bypass operations in the Oulu Univer-
sity Hospital. In all, 25 AscAA tissues and 19 control aortic tissues were
collected and analyzed with the quantitative RT-PCR method. Control aor-
tic tissues were taken during coronary bypass surgery from an area without
macroscopic atherosclerotic changes of nondilated thoracic ascending
aorta. In the immunostaining study, 12 AscAA and 5 control tissues were
used. The study was approved by the Ethical Committee of the University
of Oulu Hospital. All the study subjects gave their written informed
consent.
Measurement of Plasma Levels of OPN, MMP-2,
MMP-9, and TIMP-1 With Enzyme-Linked
Immunosorbent Assay Method
Plasma was separated by centrifuging blood samples at 1500g for 15
minutes atþ4C. Plasma samples were stored at80C. Concentrations
of OPN, MMP-2, MMP-9, and TIMP-1 in plasma were determined by
an enzyme-linked immunosorbent assay test (DOST00; R&DSystems, Eu-
rope, Abingdom, United Kingdom; and RPN2617, RPN2614, and
RPN2611; GE Healthcare, Piscataway, NJ) according to the manufac-
turer’s guidelines. All the measurements were done with sufficiently1118 The Journal of Thoracic and Cardiovascular Surdiluted plasma samples and every sample was measured in duplicate.
The mean levels of OPN, MMP-2, MMP-9, and TIMP-1 were calculated
for data analysis. All values are presented as nanograms per milliliter.
Only samples with coefficient of variation of 10% or below were used.
Quantitative RT-PCR
Aortic tissues were snap frozen with liquid nitrogen and stored at80C
until RNA extraction. RNAs from the aortic tissues were extracted using
Trizol reagent (Invitrogen, Carlsbad, Calif). In brief, 50 to 100 mg of the
tissue was homogenized in 1 mL of Trizol reagent and messenger RNA
(mRNA) was extracted according to the manufacturer’s instructions. The
extracted RNAwas purified with RNeasy Mini Kit (Qiagen Inc, Valencia,
Calif).
Complementary DNAs of mRNAs of the aortic tissues of AscAA and
control aorta were synthesized from the mRNA by cDNA First Strand
Synthesis Kit (MBI Fermentas, Heidelberg, Germany). Quantitative
RT-PCR was performed with CFX96 Real-Time PCR Detection System
(Bio-Rad Life Science, Hercules, Calif) using the following
primers: OPN (F:GCCGAGGTGATAGTGTGGTT, R:TGAGGTGATGT
CCTCGTCTG), MMP-2 (F:GCGGCGGTCACAGCTACTT, R:CACG
CTCTTCAGACTTTGGTTCT), MMP-9 (F:CCTGGAGACCTGAGAA
CCAATC, R:CCACCCGAGTGTAACCATAGC), and TIMP-1 (F:CTT
CTGGCATCCTGTTGTTG, R:AGAAGGCCGTCTGTGGGT) (Sigma-
Aldrich Co, St. Louis, Mo). Gene expression was quantified using the
SYBR Green PCR Master Mix Kit (Applied Biosystems, Foster City,
Calif). Each sample was analyzed in duplicate and an interrun calibrator
and negative control samples were included in each experiment. The quan-
titative RT-PCR conditions were as follows: 95C for 3 minutes, 40 cycles
at 95C for 10 seconds, 58C to 60C (specific for target gene) for 10 sec-
onds, and 72C for 10 seconds. The annealing temperatures of each set of
primers were 60C for OPN, 59C for MMP-2, and 58C for MMP-9 and
TIMP-1. Glyceraldehyde 3-phosphate dehydrogenase gene was used as an
endogenous control (housekeeping gene). The amount of mRNA for each
sample was normalized using the average of the pooled sample, which was
included in all plates. A melting curve analysis was included at the end of
every run. Expression levels were estimated by the normalized expression
method (DDCt) according to the manufacturer’s instructions. The relative
expression of each gene was normalized to glyceraldehyde 3-phosphate
dehydrogenase (DDCt).
Immunostaining of Aortic Tissue Samples
Paraffin-embedded sections (4 mm) of the aortic tissue were stained us-
ing the DAKO envision immunostaining method (DAKO, Glostrup, Den-
mark). First, paraffin sections were deparaffinized and rehydrated and
unmasked with high temperature and EDTA treatment. DAKO-blocking
solution was used for the blocking reaction of slides. Primary antibodies
for OPN, MMP-2, MMP-9, and TIMP-1 were monoclonal (MAB 1433,
MAB 902, MAB 911, and MAB 970; R&D Biosystems Inc, Billerica,
Mass). OPN andMMP-9 slides were incubated with the primary antibodies
for 30minutes, dilution of 1:10 for OPN and 1:100 forMMP-9. ForMMP-2
and TIMP-1, the primary antibody incubation was done overnight at 4C,
dilution 1:50 for MMP-2 and 1:100 for TIMP-1. Finally, 30-minute incu-
bation with a secondary antibody (DAKO) was used for all slides. The
binding reaction was detected using 3,30-diaminobenzidine (DAKO) and
slides were counterstained with eosin–hematoxylin.
Statistical Analysis
Differences between study groups were analyzed with the t test or
Fisher’s exact test. Inasmuch as all the measured variables were not nor-
mally distributed, the Mann-Whitney U test was used for skewed distribu-
tions. For normal distributions, the Student t test was used. All data
obtained by the plasma analysis study are shown as median and interquar-
tile range. Multivariate odds ratios (OR) with 95% confidence interval (CI)gery c April 2013
TABLE 1. Demographic characteristics of the study groups in plasma
analysis study
AscAA Controls AAA
No. of subjects 97 78 23
Age (y) 60 (10.3) 60 (13.4) 65 (6.4)*
Male 75 (77%) 55 (71%) 20 (100%)
Hypertension 48 (49%)y 22 (28%) 14 (61%)y
Diabetes 7 (7%) 4 (5%) 3 (13%)
CAD 22 (23%) 13 (17%) 12 (52%)z,x
Dyslipidemia 20 (21%) 50 (64%) 7 (30%)
Operated for AscAA 76 (78%) — —
Time from aortic operation (y) 3.9 — —
Statin in use 31 (32%) 9 (12%) 13 (57%)
Aspirin in use 15 (15%) 13 (17%) 13 (57%)
Beta-blocker in use 66 (68%) 17 (22%) 14 (61%)
ACE inhibitor in use 26 (27%) 4 (5%) 6 (26%)
Calcium channel blocker in use 23 (24%) 6 (8%) 4 (17%)
Angiotensin II receptor blocker
in use
9 (9%) 2 (3%) 4 (17%)
Mean agewith standard deviation is shown.AscAA,Ascending aortic aneurysm;AAA,
abdominal aortic aneurysm; CAD, coronary artery disease; ACE, angiotensin-
converting enzyme. *Statistical significance difference of age between AAA and As-
cAA groups is shown P<.05 (independent t test). For other variables, number of sub-
jects (percentage) is shown. Statistical significances between aneurysm groups and
controls are shown as yP< .01 (Fisher’s exact test) and zP< .005 (Fisher’s exact
test). xStatistical significance between AscAA and AAA is shown as P<.01 (Fisher’s
exact test).
Huusko et al Evolving Technology/Basic Sciencefor OR were calculated using logistic regression analysis. Quantitative
RT-PCR results are presented as median of normalized expression and stan-
dard deviation. Results were analyzed with PASWStatistics (version 18 for
Windows; SPSS, Chicago, Ill).RESULTS
Study Subjects
The main characteristics of the plasma analysis study
subjects are presented in Table 1. The mean age of the
AscAA patients and healthy controls was 60 years. For
AAA patients, the mean age was 65 years. In all, 49% of
AscAA patients had hypertension, 7% diabetes, 23% coro-
nary artery disease (CAD), and 21% dyslipidemia. AAA
patients were more likely to have CAD (P< .005). Both
AscAA and AAA patients more commonly had hyperten-
sion (P< .01 for both aneurysm types) than subjects in
the control group. When AscAA and AAA groups were
compared, patients in the AAA group were older than their
counterparts in the AscAA group (P<.05). Furthermore,
patients in the AAA group more frequently had CAD than




The OPN, MMP-2, MMP-9, and TIMP-1 levels from the
plasma were measured from a total of 198 plasma samples.
The medians with quartiles of the 4 studied proteins in each
group are presented in Figure 1. Men and women are con-
sidered as 1 group in the analysis inasmuch as there wereThe Journal of Thoracic and Carno significant differences betweenmale and female subjects
in the concentrations of the proteins measured.
Plasma OPN levels were higher in AscAA patients
(median, 94 ng/mL) and in AAA patients (median, 85 ng/
mL) compared with control subjects (median, 51 ng/mL)
(P<.001 for the both differences) (Figure 1). There were
no significant differences between the AscAA and AAA
groups or between operated and nonoperated AscAA
groups.
Plasma MMP-2 levels were higher in AscAA patients
(median, 1228 ng/mL) and in AAA patients (median,
1171 ng/mL) compared with control subjects (median,
912 ng/mL) (P<.001 for both differences) (Figure 1). No
differences were found in the comparison of operated and
nonoperated AscAA patients.
MMP-9 median levels were significantly higher
(P< .001) in patients with AscAA (80 ng/mL) compared
with healthy individuals (20 ng/mL) (Figure 1). For patients
with AAA, the median value ofMMP-9 was higher (120 ng/
mL) than the corresponding values in patients with AscAA
(P<.05) and in healthy individuals (P<.001). When oper-
ated and nonoperated AscAA patients were compared, there
was a significant difference (P<.05) between these 2 groups
(median, 63 ng/mL for operated and 108 ng/mL for nonop-
erated AscAA patients).
TIMP-1 levels were similar in all groups with a median of
156 ng/mL for patients with AscAA, 157 ng/mL for patients
with AAA, and 154 ng/mL for controls (Figure 1). No dif-
ferences were detected between operated and nonoperated
AscAA patients.
There was no correlation between aneurysm size and
plasma levels of any studied proteins. Increased risk for an-
eurysm associated with elevated levels of OPN and MMPs
was evident when patients were divided into the tertiles
based on their plasma levels of OPN, MMP-2, or MMP-9.
In the highest tertiles of OPN, MMP-2, and MMP-9, the
risk for AscAAs was highest (OR, 26 [95% CI, 8.9-75.8],
P<.001 for OPN; OR, 9 [95% CI, 3.5-22.5], P<.001 for
MMP-2; OR, 28 [95 % CI, 9.5-83.0], P < .001 for
MMP-9) compared with the first tertile (lowest plasma pro-
tein levels) by logistic regression analysis (adjusted for age
and gender). For AAAs, significant risk was obtained in the
highest tertile of OPN (OR, 10 [95%CI, 2.3-48.5],P<.005)
and MMP-2 (OR, 13.7 [95% CI, 1.4-134.0], P<.05).
Quantitative PCR Analyses of AscAA and Controls
The mean age for the AscAA patients was 59 years and
for the controls it was 63 years. In the quantitative RT-
PCR analysis of AscAA and control samples OPN,
MMP-2, and MMP-9 gene expressions were significantly
elevated in AscAA samples as compared with control sam-
ples (Table 2). AscAA samples expressed 8 times more
OPN mRNA than control samples (expression value of
0.05 for AscAAs and 0.006 for controls). MMP-2diovascular Surgery c Volume 145, Number 4 1119
FIGURE 1. Analysis of plasma protein levels of OPN, MMP-2, MMP-9, and TIMP-1. ***Statistical significances between aneurysm groups and controls
are shown P<.001 (Mann-Whitney U test). AscAA,Ascending aortic aneurysm; AAA, abdominal aortic aneurysm;OPN, osteopontin;MMP-2,matrix met-
alloproteinase type 2; MMP-9, matrix metalloproteinase type 9; TIMP-1, tissue inhibitor of matrix metalloproteinases type 1.




Sexpression was 2 times higher in AscAA samples as com-
pared with control samples; expressions of MMP-2 were
1.18 for AscAA samples and 0.54 for control samples. As-
cAA samples expressed 16 times more MMP-9 mRNA
compared with control samples, expression rates of 0.13
of AscAAs compared with 0.008 of controls. There were
no differences in gene expressions of TIMP-1 (AscAA
0.52 vs controls 0.53) between these 2 groups.TABLE 2. Gene expression results for OPN, MMP-2, MMP-9, and
TIMP-1
Gene AscAA DDC(t)(SD) Control DDC(t)(SD) Fold change
OPN 0.05 (5.17)* 0.006 (0.27) 8.3
MMP-2 1.18 (0.79)y 0.54 (0.29) 2.2
MMP-9 0.13 (2.46)* 0.008 (0.03) 16.3
TIMP-1 0.52 (0.89) 0.53 (0.26) 1.0
Quantitative real-time polymerase chain reaction results are calculated with the
DDC(t) method. OPN, Osteopontin; MMP-2, matrix metalloproteinase type 2;
MMP-9, matrix metalloproteinase type 9; TIMP-1, tissue inhibitor of matrix
metalloproteinases type 1; AscAA, ascending aortic aneurysm; SD, standard devia-
tion. Statistical significance differences between AscAA and control group are shown
as *P<.05 and yP<.001 (Mann Whitney U test). Fold change is calculated AscAA
DDC(t)/Control DDC(t).
1120 The Journal of Thoracic and Cardiovascular SurImmunostaining of Aortic Tissues
In the aortic tissue samples, the mean age of the AscAA
patients was 57 years and that of the controls was 69 years
(P<.05). Figure 2 shows immunostaining results of speci-
mens from AscAA and control aorta. Table 3 shows quali-
tative levels of staining reactions for the studied proteins
on the slides. Immunostaining of OPN in aortic lesions
revealed elevated amounts of OPN in the AscAA group
(Figure 2, A) as compared with control tissues (Figure 2,
B). It was predominantly the media in the aortic lesions
that stained by the OPN antibody in both groups.
The immunostained areas ofMMP-2 were muchmore in-
tense in AscAA samples (Figure 2, C) than in controls
(Figure 2, D). With respect to TIMP-1, immunostaining
was observed in the media of the AscAA samples. In the
controls, there were only very slight or no reactions at all
detectable for the TIMP-1 antibody.DISCUSSION
The purpose of the present study was to explore OPN,
MMP-2, MMP-9, and TIMP-1 protein levels in plasmagery c April 2013
FIGURE 2. Immunostaining study results of OPN and MMP-2 (original magnification 320). Immunohistochemistry of OPN in AscAA tissue (A) and
control tissue (B). Immunoreactivity ofMMP-2 in AscAA tissue (C) and in control tissue (D). Histologic features of aortic wall are stained with hematoxylin
and eosin. OPN, Osteopontin; MMP-2, matrix metalloproteinase type 2; AscAA, ascending aortic aneurysm.
Huusko et al Evolving Technology/Basic Sciencefrom the patients of AscAA, AAA, and controls. Aortic tis-
sue samples and gene expression levels of the aortic sam-
ples were analyzed from the patients with AscAA and
controls. Our study showed significantly elevated plasma
levels of OPN, MMP-2, and MMP-9 in AscAA and AAA
patients. In addition, plasma levels of MMP-9 were higher
in nonoperated than in operated AscAA patients. The
gene expression analysis revealed significantly increased
expression levels of OPN, MMP-2, and MMP-9 from the
tissues of AscAA patients.
Two previous studies have reported significantly higher
OPN concentrations in the serum of AAA patients.2 In
our study, both aneurysm patient groups (AscAA and
AAA) exhibited increased amounts of OPN protein levels
in plasma. Furthermore, we found increased immunoreac-
tivity for OPN in aneurysm tissues, and this led us to pro-







Staining reaction levels are presented asþþ andþ. AscAA, Ascending aortic an-
eurysm; OPN, osteopontin; MMP-2, matrix metalloproteinase type 2; MMP-9,
matrix metalloproteinase type 9; TIMP-1, tissue inhibitor of matrix metallopro-
teinases type 1.




Saneurysm disease. Studies with transgenic mice have indi-
cated that OPN-deficient mice had reduced formation of
AAA.8 Previously, it has been shown that in patients with
AscAA, an early increase in the OPN mRNA levels is typ-
ical.9 Also in our study, the mRNA levels of OPN were el-
evated in the AscAA group. This kind of increase in the
OPN mRNA level leads to the phenotypic change in the
smooth muscle cells.10 increased production of MMP-2
mRNA, and increased production of MMP-9 mRNA.9
MMPs are regulated at many different levels: transcrip-
tion of genes, synthesis of inactive zymogens, and MMP
and TIMP interactions. It is widely known that RNA levels
of MMPs (1,2,9) are increased during the formation of
aneurysm at the arterial wall of different origins.7,11,12 In
the present study, we found increasedMMP-2 mRNA levels
in the AscAA patient group, and MMP-2 plasma protein
levels were increased in both aneurysm patient groups. Ear-
lier studies examining MMP-2 have reported contradictory
results in relation to aortic aneurysms. The MMP-2 activity
in plasma has been found to be either decreased13 or un-
changed14 in patients with AAA compared with the subjects
without AAA. Patients with bicuspid aortic valve and
AscAA had increased expression ofMMP-2 in AscAA sam-
ples.15,16 On the other hand, the MMP-2 activity was found
to be reduced in aortic samples of patients with AscAA
(either with or without atherosclerosis), but its expression
was found to be increased in the AscAA patients with ath-
erosclerosis.17 In patients with aortic dissection, no increase
in plasma MMP-2 levels was detected.18,19 Previous studiesdiovascular Surgery c Volume 145, Number 4 1121




Shave shown that MMP-2 is involved in the expansion of an-
eurysm and in the healing process in aortic tissues.20 In our
immunostaining studies, MMP-2 displayed a very strong re-
action in the sections of AscAA samples, whereas in the
corresponding sections of controls no staining was detected.
The role ofMMP-9 is widely established in the formation
of aortic aneurysms.21 We found significantly increased
amounts of MMP-9 gene expression in AscAA samples.
These results are in line with the previous study, in which
MMP-9 mRNA levels were found to be higher in nonather-
osclerotic AscAAs compared with controls,17 although in
the study of Wilton and coworkers,22 MMP-9 gene expres-
sion was reported to be unchanged in AscAAs. We found el-
evated plasma levels of MMP-9 for both studied aneurysm
types. Additionally, the levels of MMP-9 were significantly
higher in the nonoperated patient group of the AscAAwhen
compared with the operated group of AscAA, and this asso-
ciation should be verified in further studies in samples taken
before and after aortic operations in patients with AscAA.
It is widely known that MMP-1 and MMP-9 levels are sig-
nificantly elevated in cases of AAA rupture.23 It seems that
MMP-9 plays a critical role in the progression of aneurysm
rupture when the aorta is expanding and inflammatory cells
are overproducing MMP-9 protein.9 Atherosclerosis is
a risk factor for AAAs, and according to many studies,
the prevalence of CAD is significantly greater among
AAA patients.24 This is in line with our study, in which
the prevalence of CAD was 52% among AAA patients,
23% among AscAA patients, and 17% in controls.
TIMP-1 protein levels seemed to be the same in aneu-
rysm and control groups according to the results of plasma
analysis and immunostaining studies. Furthermore, TIMP-1
mRNA levels were similar in the gene expression study of
AscAAs and controls. According to our findings, TIMP-1
is likely to have only minor importance in the progression
of aortic aneurysms.
The results of AscAA and AAA patient samples were in
line with the aforementioned hypothesis. Plasma protein
levels of OPN, MMP-2, and MMP-9 were significantly in-
creased in both aneurysm patient groups in comparison
with controls. Furthermore, aortic tissue mRNA levels
were significantly up-regulated in the tissues of AscAA.
Although these studied 2 aneurysm types have different
pathologic origins (AAA is atherosclerotic, whereas
AscAA is characterized by connective tissue destruction),
the same proteins seem to play active roles during aneurysm
formation and no difference was detected in our study be-
tween AAAs and AscAAs.
Our study demonstrated that OPN, MMP-2, and MMP-9
plasma protein levels and gene expression are significantly
elevated in the samples of AscAA patients, and these pro-
tein and gene expression results are in line with each other.
These proteins seem to occupy a central role in the
formation of aortic aneurysms. Furthermore, in our study,1122 The Journal of Thoracic and Cardiovascular SurMMP-9 was significantly higher in the nonoperated AscAA
group compared with the operated group of AscAA pa-
tients; we speculate that MMP-9 is a strong indicator for
enlargement of aneurysm.
This study has some limitations. In the immunostaining
study, the controls were significantly older than the AscAA
patients. However, in the plasma analysis and quantitative
RT-PCR studies, the mean age of the study subjects was
the same in all groups. Furthermore, the sample size could
have been larger in the immunostaining and quantitative
RT-PCR studies. Plasma studies for the proteins of OPN,
MMP-2, MMP-9, and TIMP-1 were done for the indepen-
dent specimens and were not matched to subjects in
whom tissue was analyzed for the same proteins. Despite
these limitations, it was possible to reveal altered protein
expression for OPN, MMP-2, and MMP-9 in AscAA and
AAA samples and, furthermore, altered gene expression
for these same proteins for AscAAs. Future studies are
needed to confirm whether these 3 proteins could be used
for the estimation of risk for AscAAs or AAAs to monitor
the progression of these diseases or to guide in therapeutic
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